Mobile

Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012270-12

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine reversibility of eGFRMDRD decrease following 52 weeks of 150 μg aleglitazar treatment and 8 weeks follow up observation after the last study medication, in patients with T2D and moderate renal function impairment (CKD stage 3), in comparison with Actos® treatment.

Critère d'inclusion

  • Type 2 diabetes with moderate renal function impairment

Liens